Victory Capital Management Inc Arcus Biosciences, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 48,482 shares of RCUS stock, worth $712,685. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,482

Previous 49,702 2.45%

Holding current value

$712,685

Previous $756,000 1.98%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$13.69 - $18.01 $16,701 - $21,972	-1,220 Reduced 2.45%	48,482 $741,000
Q2 2024 Aug 05, 2024	SELL	$14.59 - $18.48 $373,854 - $473,531	-25,624 Reduced 34.02%	49,702 $756,000
Q1 2024 May 03, 2024	SELL	$14.83 - $20.18 $431,360 - $586,975	-29,087 Reduced 27.86%	75,326 $1.42 Million
Q4 2023 Feb 05, 2024	BUY	$13.43 - $19.63 $487,670 - $712,804	36,312 Added 53.32%	104,413 $1.99 Million
Q3 2023 Nov 06, 2023	SELL	$17.62 - $23.54 $106,812 - $142,699	-6,062 Reduced 8.17%	68,101 $1.22 Million
Q2 2023 Jul 27, 2023	SELL	$16.97 - $22.03 $337,753 - $438,463	-19,903 Reduced 21.16%	74,163 $1.51 Million
Q1 2023 May 02, 2023	BUY	$15.96 - $23.15 $453,311 - $657,529	28,403 Added 43.26%	94,066 $1.72 Million
Q4 2022 Feb 10, 2023	BUY	$19.7 - $35.71 $59,494 - $107,844	3,020 Added 4.82%	65,663 $1.36 Million
Q4 2022 Feb 09, 2023	BUY	$19.7 - $35.71 $886,165 - $1.61 Million	44,983 Added 254.72%	62,643 $1.3 Million
Q3 2022 Nov 02, 2022	BUY	$23.23 - $30.07 $44,090 - $57,072	1,898 Added 12.04%	17,660 $462,000
Q2 2022 Aug 01, 2022	SELL	$17.23 - $37.73 $25,310 - $55,425	-1,469 Reduced 8.53%	15,762 $399,000
Q1 2022 May 04, 2022	BUY	$28.92 - $41.83 $300,305 - $434,362	10,384 Added 151.66%	17,231 $417,000
Q4 2021 Feb 07, 2022	SELL	$31.38 - $48.47 $13,681 - $21,132	-436 Reduced 5.99%	6,847 $277,000
Q3 2021 Nov 02, 2021	SELL	$26.93 - $37.68 $1.71 Million - $2.4 Million	-63,577 Reduced 89.72%	7,283 $254,000
Q2 2021 Aug 03, 2021	SELL	$22.75 - $35.77 $33.2 Million - $52.2 Million	-1,459,488 Reduced 95.37%	70,860 $1.95 Million
Q1 2021 May 04, 2021	BUY	$26.16 - $41.39 $10.4 Million - $16.5 Million	397,786 Added 35.12%	1,530,348 $43 Million
Q4 2020 Feb 01, 2021	SELL	$17.0 - $32.36 $951,949 - $1.81 Million	-55,997 Reduced 4.71%	1,132,562 $29.4 Million
Q3 2020 Nov 09, 2020	BUY	$17.14 - $25.47 $5.07 Million - $7.54 Million	295,955 Added 33.16%	1,188,559 $20.4 Million
Q2 2020 Aug 07, 2020	BUY	$13.97 - $36.56 $12.4 Million - $32.5 Million	887,758 Added 18319.4%	892,604 $22.1 Million
Q1 2020 May 04, 2020	SELL	$8.78 - $19.28 $965 - $2,120	-110 Reduced 2.22%	4,846 $67,000
Q4 2019 Feb 04, 2020	BUY	$7.33 - $10.79 $3,408 - $5,017	465 Added 10.35%	4,956 $44,000
Q3 2019 Nov 12, 2019	BUY	$6.44 - $10.18 $28,922 - $45,718	4,491 New	4,491 $41,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Arcus Biosciences, Inc. Transaction History